



INTELLIGENT INFORMATION

Market Research Report

Red Listed Products Study

Original Questionnaire

Q1 For Which Primary Care Trust (PCT) do you currently work?

Open-ended

Q2 Are you currently, or do you expect to be, involved in decisions relating to formulary or recommended product lists in your PCT?

Yes

No [Screen out]

A recent study has found that over half of the English PCTs are adding drugs to their 'Red lists' of products that can only be prescribed by a Consultant in secondary care. (<http://www.telegraph.co.uk/health/healthnews/8446782/Patients-are-denied-high-cost-drugs-by-NHS-trusts.html>)

Q3 Does your PCT have a red list of products which GPs cannot prescribe, and can only be used by hospital Consultants?

Yes

No [screen out?]

Unsure [screen out?]

Q4 Approximately how many individual drugs comprise this list?

[drop down list]

1

2

3

Etc.

20+

Q5 Who would typically make the decision to add a product to such a list?

Please provide job or committee titles where possible

Open-ended

Q6 How often would your PCT review products with the intention of adding them to the red list?

Open-ended

Q7 Please select the top 3 therapy areas in which your PCT is looking to save money by adding products to the red list.

Cardiology
Chest medicine
Cytology
Dermatology
Endocrinology
Gastroenterology
Genitourinary
Gynaecology
Haematology
Immunology
Lipidology
Nephrology
Neurology
Ophthalmology
Orthopaedic
Otorhinolaryngology
Palliative
Psychiatric
Rheumatology
Urology
Other, please specify _____

Q8 Please describe the process by which products come under consideration for adding to the red list?
Open-ended

Q9 What criteria would decide whether a product was put on the red list?
Please select all that apply

Total drug expenditure high [go to Q10]
Total drug expenditure too high [go to Q11]
Total drug expenditure has risen unacceptably [go to Q12]
The patent of the branded drug has expired
Other, please specify _____

Q10 What level of expenditure is considered high?

Open-ended

Q11 What level of expenditure is considered too high?

Open-ended

Q12 What level of increase has been considered unacceptable?

Open-ended

Q13 Are you aware of any drugs that your PCT is considering ADDING to its red list?
Please list as many as applicable

Or: Unsure

[Repeat Q14 for all at Q13]

Q14 For what reason(s) would you add [Answer from Q13] to the red-list, other than cost?

- Not cost effective in short term
- Not cost effective in long term
- New clinical evidence
- Cheaper alternative available
- Generic available
- Should be prescribed by specialists
- Lifestyle changes preferable to medicine
- Cost is the only factor
- Other, please specify _____

Q15 Are there any drugs currently on the red list that you would like to return to the green list?

Please list all that apply

Or: None [Go to Q17]

Q16 What would the manufacturers need to do in order to have their product returned to the green list?

Open-ended

Q17 How effective do you feel that the measure of preventing certain drugs from being prescribed in primary care is in saving money for PCTs?

10 = Very effective | 9 | 8 | 7 | 6 | 5 | 4 | 3 | 2 | 1 = Not at all effective

Q18 Why do you say that?

Open-ended

Q19 How do you feel that the use of red-lists to prevent the prescription of certain products in primary care will change over the next 2 years in your PCT?

Increase significantly
Increase slightly
Stay about the same
Decrease slightly
Decrease significantly
Unsure [go to Q21]

Q20 Why do you feel that the use of red-lists will [Answer from Q17] over the next 2 years?

Open-ended

Q21 What measures would a pharmaceutical company need to take to prevent more of its products from being red-listed?

Open-ended

Q22 Does your PCT have an amber list of products?

Yes
No [go to Q24]

Q23 What are the criteria for a product to be moved to the amber list?

Open-ended

Q24 What methods of drug expenditure reduction, other than red-listing products, have you identified in order to cut the costs for your PCT?

Open-ended

Q25 Do you believe there are likely to be any adverse consequences of implementing these planned changes? If so what are they?

Open-ended

Q26 If you have any comments or other questions on the subject or questionnaire, please write them here.

Open-ended

Medix Contact Details

MedixGlobal, 15 Meadway Court,
Stevenage, SG1 2EF, United Kingdom
Tel: 01763 853303
Fax: 01763 853573
E-Mail: me@medixglobal.com
Website: <http://www.medixglobal.com/>

Research Director: Mehdi Ehtesham